ASSOCIATION OF THE ADRB2 GENE POLYMORPHIC VARIANT C79G (rs1072714) WITH THE COURSE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN OBESE AND NON-OBESE PATIENTS

Stupnytska, Ganna; Горовенко, Н. Г.; Podolska, S.V.; Kit, Zoriana; Шеремет, М. І.; Kovtun, A. I.; Nesterovska, Olga

doi:10.12955/cbup.v6.1278

Cited by 5 publications

(4 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…За даними різних досліджень, у патогенезі ХОЗЛ важливу роль відіграють різноманітні гени, які мають вплив на процеси запалення, фіброзу та ре-гуляції реактивності бронхів [10,11]. Зокрема із розвитком [13], тяжкістю перебігу ХОЗЛ [6] та відповіддю до бета-2 агоністів асоціюється поліморфізм гена ADRB2 [12].…”

Section: вступunclassified

Impact of pharmacotherapy with tiotropium/olodaterol on the pulmonary function in COPD patients depending on the Arg16Gly polymorphism of ADRB2 gene

Dmytriiev¹,

Mostovoy²,

Slepchenko³

2022

Rep. of Vinnytsia Nation. Med. Univ.

View full text Add to dashboard Cite

Annotation. Chronic obstructive pulmonary disease (COPD) is a prevalent chronic disease. Endogenic or genetic factors play a significant role in the COPD development. The aim of our study was to investigate a response to the tiotropium/olodaterol treatment in patients with different ADRB2 gene polymorphism. 100 patients with the diagnosis of COPD were included into the study. Pulmonary function testing was performed during all study visits. All patients received treatment according to GOLD 2019, which included a combination of long-acting beta-2 agonists (LABA) and long-acting muscarinic antagonists (LAMA). According to the results of genetic testing all patients were divided into 3 groups: Arg16Arg – 23 patients (23%), Arg16Gly – 39 patients (39%), Gly16Gly – 38 patients (38%). Statistical processing of research materials was carried out using the SPSS statistical program package for Windows version 26.0. Descriptive statistics were determined for each interval variable and presented as mean ± standard deviation (SD). Kolmogorov-Smirnov test, Mann-Whitney test and T-test, Wilkson test, t-test, Kruskal-Wallis test were used as part of the one-way ANOVA analysis, as well as with the analysis of covariance (ANCOVA) followed by pairwise comparison of groups using Bonferroni corrections. Groups did not differ by sex, age, part of smokers, COPD duration. There was significant difference in RLM at the time of inclusion (p=0.01). There was a significant difference in the Pain value at the time of study completion (р=0.024). When comparing values of SGRQ questionnaire, there was a significant difference in the scales of Impact (р=0.006) and Total score (р=0.021). Thus, group Gly16Gly had better dynamics of SF-36 and SGRQ values during the study. Despite the absence of significant difference we can state, that Gly16Gly genotype has better response to treatment when compared to Arg16Arg, which is probably conditioned by the development of sensitization of ADRB2 receptor in Arg16Arg group.

show abstract

Section: вступunclassified

Impact of pharmacotherapy with tiotropium/olodaterol on the pulmonary function in COPD patients depending on the Arg16Gly polymorphism of ADRB2 gene

Dmytriiev¹,

Mostovoy²,

Slepchenko³

2022

Rep. of Vinnytsia Nation. Med. Univ.

View full text Add to dashboard Cite

show abstract

“…But multiple studies indicate an important role of different genes in the regulation of inflammation, fibrosis and airways responsiveness [11]. One of such genes, that was shown to be related to the COPD development [12] and severity [13], and also response to beta-2 agonists, is beta-2 adrenergic receptor (ADRB2) gene [14].…”

Section: Introductionmentioning

confidence: 99%

Clinical course of COPD in patients with Arg16Gly (rs1042713) polymorphism of <em>ADRB2</em> gene

Dmytriiev

Mostovoy

Slepchenko

et al. 2022

Monaldi Arch Chest Dis

View full text Add to dashboard Cite

The ADBR2 gene has been studied for its possible relationship with the development and clinical course of chronic obstructive pulmonary disease (COPD), including response to beta-2 agonists, with existing data being contentious on the subject. So, the purpose of this study was to look into the potential impact of the arginine-16-glycine (Arg16Gly) polymorphism on the clinical course and drug utilization in COPD patients. Data show that patients with Arg16Arg have a lower number of hospital admissions for exacerbations (p=0.048), but only in the total number of exacerbations, including those treated out-patients (p=0.086). Each glycine (Gly) copy was associated with a higher number of exacerbations (OR: 0.25; 95% CI: 0.00-055; p=0.048). The number of exacerbations after LABA/LAMA treatment was similar across groups, indicating that all ADRB2 variants responded well to the treatment. Furthermore, there were no statistically significant differences in mMRC and CAT values across all study visits. Interestingly, groups differed in their use of antibiotics (AB) at all visits, with Arg16Arg being associated with the least amount of AB use. There was also a link discovered between clycine copies and increased use of glucocorticoids. As a result, Arg16Gly is involved in the clinical course of COPD as well as the utilization of drug groups. Based on the findings, we can speculate that the cross-talk between the ADRB2 gene and the corticosteroid receptor is altered in patients with the Gly16Gly genotype.

show abstract

“…As has been stated in guidelines, COPD development requires a combination of environmental and internal factors, and multiple studies have suggested an important role for several genes related to the regulation of inflammation, fibrosis, and airway responsiveness 11 . One of these is adrenoreceptor beta 2 (ADRB2), which some studies have shown to be related to COPD development 12 , severity 13 , and response to beta-2 agonists 14 . One study showed varying prevalence of ADRB2 gene alleles in COPD patients and healthy controls 15 and there is also data suggesting that ADRB2 polymorphisms are related to the response to inhaled corticosteroids 16, 17 .…”

Section: Introductionmentioning

confidence: 99%

Does the Gln27Gln polymorphism of the adrenoreceptor beta 2 gene affect the clinical course of chronic obstructive pulmonary disease?

Dmytriiev¹,

Mostovoy²,

Slepchenko³

et al. 2022

Biomed. Res. Ther.

View full text Add to dashboard Cite

Introduction: Many recent guidelines have highlighted the importance of genetic factors in chronic obstructive pulmonary disease (COPD) development. Adrenoreceptor beta 2 (ADRB2) is believed to be linked to the response to beta 2 agonists. However, the data for this gene remains controversial. In our study we aimed to investigate the impact of the Gln27Glu gene polymorphism of ADRB2 on the clinical course of COPD. Methods: 100 patients were included into the study. We assessed GOLD group, number of exacerbations, hospitalizations, modified Medical Research Council (mMRC) dyspnea and COPD assessment test (CAT) scores, and the utilization of antibiotics, glucocorticoids, and xanthines in these patients, as well as genetic testing at inclusion. All patients had their medication changed to tiotropium/olodaterol. Results: Groups did not differ according to age, sex, smoking status, pack-years, or COPD duration. We found that patients with the Gln27Gln polymorphism had the lowest GOLD grading, D. No difference was found in the number of exacerbations, hospitalizations, and out-patient exacerbations in the year prior to inclusion and the study year. Tiotropium/olodaterol were comparable in all study groups in reducing exacerbations and hospitalizations. There was no significant difference in mMRC and CAT values between the groups. We found that Gln27Gln patients required less antibiotics at inclusion and less glucocorticoids at the end of the study. Tiotrpium/olodaterol showed variable results for different genotypes regarding the reduction in use of different drugs. Conclusion: This ADRB2 polymorphism was associated with the progression of COPD as it is linked to a more severe phenotype, requiring greater use of antibiotics and glucocorticoids. This indicates potential crosstalk at the cellular level between ADRB2 and glucocorticoid receptors and should be investigated further.

show abstract

ASSOCIATION OF THE ADRB2 GENE POLYMORPHIC VARIANT C79G (rs1072714) WITH THE COURSE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN OBESE AND NON-OBESE PATIENTS

Cited by 5 publications

References 31 publications

Impact of pharmacotherapy with tiotropium/olodaterol on the pulmonary function in COPD patients depending on the Arg16Gly polymorphism of ADRB2 gene

Impact of pharmacotherapy with tiotropium/olodaterol on the pulmonary function in COPD patients depending on the Arg16Gly polymorphism of ADRB2 gene

Clinical course of COPD in patients with Arg16Gly (rs1042713) polymorphism of <em>ADRB2</em> gene

Does the Gln27Gln polymorphism of the adrenoreceptor beta 2 gene affect the clinical course of chronic obstructive pulmonary disease?

Contact Info

Product

Resources

About